Psychedelic News2021-09-02T07:51:07+00:00

Industry News

News and Press Releases

  • Palliateive Care | Natural Psilocybin | Psychedelics

In Conversation With Dr Amza Ali on Palliative Care

September 20, 2021|

Dr Amza Ali, neurologist and global medical director at Psyence shares some more light on this subject explaining what palliative care is, why it needs more attention and what Psyence’s vision and mission are when it comes to improving the access to and the effectiveness of palliative care globally.

  • Dr Amza Ali | Palliative Care | Psyence

The Diaries of a Psychedelic Exec : Episode 8

September 8, 2021|

This week we continue to hear from Dr Amza Ali, neurologist and global medical director at Psyence about palliative care, and Psyence’s vision for making a positive impact on the lives of people suffering from serious illnesses.

Psyence Group announces the commencement of online sales and distribution of “GOODMIND™” products

August 18, 2021|

We are excited that as of today our functional mushroom nutraceutical product, GOODMIND™ is available online. The GOODMIND™ formulas harness the power of adaptogens, these are non-toxic, non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits. GOODMIND™ is designed to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress.

  • Diary of a psychedelic exec | episode 06 | Psyence

The Diaries of a Psychedelic Exec : Episode 6

July 22, 2021|

Hi, I am Neil Maresky, the new CEO of Psyence. I am delighted to be able to make a contribution to the “Diary of a Psychedelic Exec”. In this episode I reflect on the challenges society is facing when it comes to mental health and why I think psychedelics, and Psyence in particular, have an important role to play in addressing these challenges. I feel privileged to have the opportunity to lead an incredible team at Psyence, all of whom are clearly committed to making an impact on society.

  • Natural Psilocybin | Psyence

Why Natural Psilocybin?

July 15, 2021|

We believe that natural psilocybin offers multiple benefits for the long-term treatment of mental health conditions that may result from trauma. Plant-based and natural remedies are our preferred route as conscious consumers increasingly seek more natural treatments when it comes to supporting their mental wellbeing.

  • The Diaries of a Psychedelic Exec : Episode 4

The Diaries of a Psychedelic Exec : Episode 5

July 12, 2021|

It was another exciting week at Psyence as we welcomed Dr. Neil Maresky as Chief Executive Officer of Psyence Group. Based in Canada, Neil brings over twenty years of biopharmaceutical experience to Psyence; he was previously at AstraZeneca. I am now the Executive Chairman of Psyence Group and will work closely with Neil on all aspects of the business going forward. I am also delighted to share news of our partnership agreement with Clerkenwell Health; a leading psychedelic Contract Research Organisation based in the United Kingdom.

  • Clerkenwell | Psyence | Psilocybin

Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical Trial

July 7, 2021|

Psyence has signed a partnership agreement with Clerkenwell Health, a leading psychedelic Contract Research Organisation (CRO) based in the United Kingdom to develop market leading clinical trials in the field of palliative care. Clerkenwell will be responsible for jointly designing and delivering the UK clinical trial. Palliative care is the treatment and alleviation of suffering for those facing a serious acute or persistent medical issue, whether the prognosis is deemed terminal or chronic and ongoing.

  • diary of psych exec | Psyence

The Diaries of a Psychedelic Exec : Episode 4

July 2, 2021|

In this week's diary I reflect on the impact of trauma in our lives following an unexpected medical emergency at home. This has fuelled my passion for what we are doing here at Psyence and the positive impact we could have on the lives of so many people.

  • Neil Maresky

Psyence Group Announces Appointment of New Chief Executive Officer

June 28, 2021|

Today Dr. Neil Maresky joins Psyence as Chief Executive Officer. Dr. Maresky brings more than 20 years of biopharmaceutical expertise to our team; he will oversee strategy and operations of Psyence, and will be based in Canada. Dr. Maresky has been instrumental in the launch, commercialization, and uptake of many ground breaking innovations, which have positively impacted the health of millions of patients across Canada.

  • World Psychedelics Day 2021 | Psyence

World Psychedelics Day 2021

June 20, 2021|

On 20 June 2021 we celebrate the inaugural World Psychedelic Day. This day has been set aside to recognise a new era of rational and informed perspectives on modern day psychedelics and traditional psychoactive plant medicines. To mark this day, we asked some of our team why they believe in the healing power of psychedelics and natural plant-based medicine.

  • The Diary of a Psychedelic CEO | Episode 03

The Diary of a Psychedelic CEO | Episode 03

June 17, 2021|

I am a strong believer that in business, one always has to mitigate risk. Yes, we are focusing on psilocybin and doing some incredibly exciting work in this space, but parallel to this we are also building a business in mental health and mental wellness.

  • Diary of a Psychedelic CEO Part 2

The Diary of a Psychedelic CEO | Episode 02

June 11, 2021|

In this episode I share the story of Psyence and how it came into being. From receiving a full license to cultivate, process, import, produce and export Psilocybin mushrooms just over a year ago, to designing and building out our commercial facility, a lot has been achieved in a short time.

  • Diary of a Psychedelic CEO Part 1

The Diary of a Psychedelic CEO | Episode 01

June 4, 2021|

It’s been an exciting four months since we listed Psyence on the CSE January 2021. My team and I have been hard at work since then, perfecting our strategy, commencing operations, product development and making sure that we are hyper focused on what we are trying to achieve.

  • GROUP_UPDATE_FEATURE

Psyence Group Corporate Update

May 27, 2021|

Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its three clear paths to revenue and value creation namely: Psyence Production, Psyence Therapeutics and Psyence Function.

  • How we grow Psilocybin Mushrooms | Psyence

How We Grow Our Psilocybin Mushrooms

May 7, 2021|

At Psyence we have sourced the world's best genetics, and coupled that with world leading expertise in the field of mycology, to produce the highest quality mushrooms. Our process is complex, but refined.

  • Psilocybin Mushroom | Psyence

Did You Know That Psilocybin Mushrooms Are Rare?

April 22, 2021|

Psilocybin is an alkaloid found in the fruits of some fungi. These fungi are rare in the wild requiring skill to find. There are various mushroom genus that contain psilocybin namely Psilocybe, Gymnopilus, Inocybe, Galerina, [...]

JV Signed With Pure Extracts

March 31, 2021|

Psyence Group Inc. (CSE: PSYG) (“Psyence”), and Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts”) and are pleased to announce the signing of a Letter of Intent (“LOI”) to form a Joint Venture (the “JV”) to develop superior techniques for the extraction of psilocybin from psychedelic mushrooms, as well as the development of advanced formulations containing psilocybin for the long-term treatment of psychological trauma and its mental health consequences.

Partnership with Base Pair Health announced

March 5, 2021|

Psyence Group Announces Partnership With Base Pair Health and Strengthens Management Team TORONTO, ON/ March 5, 2021 / Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to announce [...]

CSE conditional listing approval received

January 11, 2021|

Cardinal Capital Partners and MindHealth BioMed Receives CSE Conditional Listing Approval Toronto, Ontario-- - Cardinal Capital Partners Inc. (the "Company" or "Cardinal") and MindHealth Biomed Corp. ("MindHealth", and together with Cardinal, [...]

News and Press Releases

  • Palliateive Care | Natural Psilocybin | Psychedelics

In Conversation With Dr Amza Ali on Palliative Care

September 20, 2021|

Dr Amza Ali, neurologist and global medical director at Psyence shares some more light on this subject explaining what palliative care is, why it needs more attention and what Psyence’s vision and mission are when it comes to improving the access to and the effectiveness of palliative care globally.

  • Dr Amza Ali | Palliative Care | Psyence

The Diaries of a Psychedelic Exec : Episode 8

September 8, 2021|

This week we continue to hear from Dr Amza Ali, neurologist and global medical director at Psyence about palliative care, and Psyence’s vision for making a positive impact on the lives of people suffering from serious illnesses.

Psyence Group announces the commencement of online sales and distribution of “GOODMIND™” products

August 18, 2021|

We are excited that as of today our functional mushroom nutraceutical product, GOODMIND™ is available online. The GOODMIND™ formulas harness the power of adaptogens, these are non-toxic, non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits. GOODMIND™ is designed to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress.

  • Diary of a psychedelic exec | episode 06 | Psyence

The Diaries of a Psychedelic Exec : Episode 6

July 22, 2021|

Hi, I am Neil Maresky, the new CEO of Psyence. I am delighted to be able to make a contribution to the “Diary of a Psychedelic Exec”. In this episode I reflect on the challenges society is facing when it comes to mental health and why I think psychedelics, and Psyence in particular, have an important role to play in addressing these challenges. I feel privileged to have the opportunity to lead an incredible team at Psyence, all of whom are clearly committed to making an impact on society.

  • Natural Psilocybin | Psyence

Why Natural Psilocybin?

July 15, 2021|

We believe that natural psilocybin offers multiple benefits for the long-term treatment of mental health conditions that may result from trauma. Plant-based and natural remedies are our preferred route as conscious consumers increasingly seek more natural treatments when it comes to supporting their mental wellbeing.

  • The Diaries of a Psychedelic Exec : Episode 4

The Diaries of a Psychedelic Exec : Episode 5

July 12, 2021|

It was another exciting week at Psyence as we welcomed Dr. Neil Maresky as Chief Executive Officer of Psyence Group. Based in Canada, Neil brings over twenty years of biopharmaceutical experience to Psyence; he was previously at AstraZeneca. I am now the Executive Chairman of Psyence Group and will work closely with Neil on all aspects of the business going forward. I am also delighted to share news of our partnership agreement with Clerkenwell Health; a leading psychedelic Contract Research Organisation based in the United Kingdom.

  • Clerkenwell | Psyence | Psilocybin

Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical Trial

July 7, 2021|

Psyence has signed a partnership agreement with Clerkenwell Health, a leading psychedelic Contract Research Organisation (CRO) based in the United Kingdom to develop market leading clinical trials in the field of palliative care. Clerkenwell will be responsible for jointly designing and delivering the UK clinical trial. Palliative care is the treatment and alleviation of suffering for those facing a serious acute or persistent medical issue, whether the prognosis is deemed terminal or chronic and ongoing.

  • diary of psych exec | Psyence

The Diaries of a Psychedelic Exec : Episode 4

July 2, 2021|

In this week's diary I reflect on the impact of trauma in our lives following an unexpected medical emergency at home. This has fuelled my passion for what we are doing here at Psyence and the positive impact we could have on the lives of so many people.

  • Neil Maresky

Psyence Group Announces Appointment of New Chief Executive Officer

June 28, 2021|

Today Dr. Neil Maresky joins Psyence as Chief Executive Officer. Dr. Maresky brings more than 20 years of biopharmaceutical expertise to our team; he will oversee strategy and operations of Psyence, and will be based in Canada. Dr. Maresky has been instrumental in the launch, commercialization, and uptake of many ground breaking innovations, which have positively impacted the health of millions of patients across Canada.

  • World Psychedelics Day 2021 | Psyence

World Psychedelics Day 2021

June 20, 2021|

On 20 June 2021 we celebrate the inaugural World Psychedelic Day. This day has been set aside to recognise a new era of rational and informed perspectives on modern day psychedelics and traditional psychoactive plant medicines. To mark this day, we asked some of our team why they believe in the healing power of psychedelics and natural plant-based medicine.

  • The Diary of a Psychedelic CEO | Episode 03

The Diary of a Psychedelic CEO | Episode 03

June 17, 2021|

I am a strong believer that in business, one always has to mitigate risk. Yes, we are focusing on psilocybin and doing some incredibly exciting work in this space, but parallel to this we are also building a business in mental health and mental wellness.

  • Diary of a Psychedelic CEO Part 2

The Diary of a Psychedelic CEO | Episode 02

June 11, 2021|

In this episode I share the story of Psyence and how it came into being. From receiving a full license to cultivate, process, import, produce and export Psilocybin mushrooms just over a year ago, to designing and building out our commercial facility, a lot has been achieved in a short time.

  • Diary of a Psychedelic CEO Part 1

The Diary of a Psychedelic CEO | Episode 01

June 4, 2021|

It’s been an exciting four months since we listed Psyence on the CSE January 2021. My team and I have been hard at work since then, perfecting our strategy, commencing operations, product development and making sure that we are hyper focused on what we are trying to achieve.

  • GROUP_UPDATE_FEATURE

Psyence Group Corporate Update

May 27, 2021|

Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its three clear paths to revenue and value creation namely: Psyence Production, Psyence Therapeutics and Psyence Function.

  • How we grow Psilocybin Mushrooms | Psyence

How We Grow Our Psilocybin Mushrooms

May 7, 2021|

At Psyence we have sourced the world's best genetics, and coupled that with world leading expertise in the field of mycology, to produce the highest quality mushrooms. Our process is complex, but refined.

  • Psilocybin Mushroom | Psyence

Did You Know That Psilocybin Mushrooms Are Rare?

April 22, 2021|

Psilocybin is an alkaloid found in the fruits of some fungi. These fungi are rare in the wild requiring skill to find. There are various mushroom genus that contain psilocybin namely Psilocybe, Gymnopilus, Inocybe, Galerina, [...]

JV Signed With Pure Extracts

March 31, 2021|

Psyence Group Inc. (CSE: PSYG) (“Psyence”), and Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts”) and are pleased to announce the signing of a Letter of Intent (“LOI”) to form a Joint Venture (the “JV”) to develop superior techniques for the extraction of psilocybin from psychedelic mushrooms, as well as the development of advanced formulations containing psilocybin for the long-term treatment of psychological trauma and its mental health consequences.

Partnership with Base Pair Health announced

March 5, 2021|

Psyence Group Announces Partnership With Base Pair Health and Strengthens Management Team TORONTO, ON/ March 5, 2021 / Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to announce [...]

CSE conditional listing approval received

January 11, 2021|

Cardinal Capital Partners and MindHealth BioMed Receives CSE Conditional Listing Approval Toronto, Ontario-- - Cardinal Capital Partners Inc. (the "Company" or "Cardinal") and MindHealth Biomed Corp. ("MindHealth", and together with Cardinal, [...]

Psyence In The News

Psyence Group launches its functional mushroom products under the GOODMIND banner in South Africa

Psyence Group Inc (CSE:PSYG)’s Tony Budden caught up with Proactive New York to discuss the the international biotechnology company with operations in South Africa’s launch of its range of functional mushroom products under the GOODMIND banner.

Read More

In this interview with Proactive Investors, Dr. Neil Maresky talks about his appointment as CEO of Psyence Group.

He shares insights about his career, including spending more than a decade at AstraZeneca Canada as Vice President of Scientific Affairs. Dr. Maresky, a South African trained doctor, tells Proactive about his motivation to join Psyence, stating that it is because of its ability to potentially impact mental health including depression, anxiety, PTSD, and end-of-life care.

Take a listen here.

Read More

Psyence Group ‘delighted’ to reach psilocybin product development agreement with Jamaican government

Interested in Psyence’s collaboration with the Jamaican government’s Scientific Research Council (SRC)? Take a listen to the Proactive Investors interview with Psyence CEO Jody Aufrichtig and learn more about the agreement which will consist of three key initiatives: developing psilocybin-based nutraceuticals; identifying and collecting Jamaica’s psychedelic and psychoactive mushrooms, and sorting protocols to optimize spawn production of rare psychedelic mushroom species.

Read More

Market For Psychedelic Drugs Expected to Reach $6.9 Billion By 2027

14 April 2021

We are honoured to be referenced in an article about the growing psychedelics sector, with the market for psychedelic drugs expected to reach $6.9 billion by 2027.

Read More

Psychedelic Finance chats to Psyence CEO Jody Aufrichtig

19 January 2021

Find out why our CEO believes in psychedelics, what Psyence stands for and how the lessons Jody learnt in the cannabis industry are helping him navigate the psychedelics opportunity in this in depth Q&A with Psychedelic Finance.

Read More

Psyence looking to be a major player in psychedelics using their federally licensed facilities

11 February 2021

Interested in learning more about Psyence? Take a listen to our CEO Jody Aufrichtig’s conversation with Steve Darling from Proactive.

Read More

Jody Aufrichtig in conversation
with the CSE’s
Barrington Miller

19 February 2021

Psyence joined the CSE’s Barrington Miller to tell our story and share what we believe sets Psyence apart from other companies in this space: we are licensed, operational and global. Want to know more?

Take a look at this video:

Go to Top